Newsroom

Press Releases

See All

05/13/2025

Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
05/08/2025

Sarepta Therapeutics to Present at the BofA Securities Health Care Conference
05/06/2025

Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments

Stories & Perspectives

Advocates & Innovators

Roots of innovation: From science fairs to the leading edge of precision genetic medicine
Advocates & Innovators

Navy veteran, lifelong learner, dedicated Duchenne Nurse Educator: Meet John Crane
Inside the Science

Wearable devices and the future of rare disease clinical trials: Landry’s story
Advocates & Innovators

Awards & Recognitions: Sarepta recognized for innovation and industry leadership
Inside the Science

Journey to better understanding of LGMD: Q&A on the early findings of a new natural history study
Culture & Community

Continuing a family legacy: Meet Sarepta colleague and Duchenne advocate Shawn Marlow
Patient Voices

When time is muscle: One dad shares his story to advocate for Duchenne newborn screening
Advocates & Innovators

Guardians of the last mile: Ensuring smooth delivery and a seamless patient experience
Advocates & Innovators

A tale of two interns: Meet Kate & Katherine, rare disease advocates and members of Sarepta’s Patient Affairs team
Inside the Science

What’s in a dose? Gene therapy dosing explained (Video)
Advocates & Innovators

Seeing hope at genetic medicine's frontier: Meet Stefanie Mason, M.D.
Inside the Science

Why are steroids used in gene therapy for neuromuscular disease?
Advocates & Innovators

A passion for patients, an influential mentor and a change in plans: Meet Danielle Griffin
Patient Voices

Creating pathways to LGMD genetic diagnosis: Spotlight on LGMD Grant Award recipient
Advocates & Innovators

Ensuring the safety of clinical trial participants: Meet Eddie Darton, M.D.
Advocates & Innovators

Dragging tomorrow into today: Meet Rachael Potter, Ph.D.
Inside the Science

Understanding external controls and their importance to clinical trials for rare diseases
Inside the Science

Meaningful measure: Understanding the NSAA, an important Duchenne functional-assessment tool
Culture & Community

What’d you do this summer? Our summer interns share lessons learned
Culture & Community

Pride proud: What belonging feels like and why representation matters
Advocates & Innovators

A conversation with CFO Ian Estepan, recipient of the 2022 CFO of the Year award from the Boston Business Journal
Inside the Science

Seroprevalence: What patients should know about pre-existing antibodies to gene therapy
Inside the Science

Patient registries: A catalyst for developing new therapies for rare diseases
Inside the Science

Measurements used in clinical trials for Duchenne muscular dystrophy – an overview
Advocates & Innovators

How a collaboration in the lab led to a seat at the table in Sarepta’s Gene Editing Innovation Center
Inside the Science

Welcome to GT‐FAQ!
Advocates & Innovators

Expanding access to newborn screening for those with rare diseases
Patient Voices

Patiently waiting
Advocates & Innovators

From art to science: How one Sarepta scientist brings arts into the lab
Patient Voices

Advocacy community unites to support families
Culture & Community

How Sarepta infused its corporate brand with urgency and optimism on behalf of patients
Inside the Science

What’s in a name? A lot, for the limb-girdle muscular dystrophy community.

Media Library

Sarepta Corporate Logos, Images & Fact Sheets

Press Contact

Tracy Sorrentino
Executive Director, Public Relations
Sarepta Therapeutics, Inc.
[email protected]
617-274-4052